ES2055175T3 - Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co - Google Patents

Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co

Info

Publication number
ES2055175T3
ES2055175T3 ES90101570T ES90101570T ES2055175T3 ES 2055175 T3 ES2055175 T3 ES 2055175T3 ES 90101570 T ES90101570 T ES 90101570T ES 90101570 T ES90101570 T ES 90101570T ES 2055175 T3 ES2055175 T3 ES 2055175T3
Authority
ES
Spain
Prior art keywords
acid
therapy
preparation
pharmaceutically acceptable
acceptable salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90101570T
Other languages
English (en)
Inventor
Grazie Christina Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioresearch SRL
Original Assignee
Bioresearch SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioresearch SRL filed Critical Bioresearch SRL
Application granted granted Critical
Publication of ES2055175T3 publication Critical patent/ES2055175T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DE ACIDO 5-METILOTETRAHIDROFOBICO, DE ACIDO 5-FORMILO- TETRAHIDROFOBICO Y DE SUS SALES FARMACEUTICAMENTE ACEPTABLES PARA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS, LIBERABLES EN FORMA CONTROLADA, ADECUADAS PARA EL USO EN LA TERAPIA DE DISTURBIOS DEPRESIVOS, EN PARTICULAR DEPRESION MAYOR, DISTIMIA O NEUROSIS DEPRESIVA Y OTROS DISTURBIOS DEPRESIVOS NO ESPECIFICADOS, INDEPENDIENTEMENTE DE LOS NIVELES PLASMATICOS, Y A LAS COMPOSICIONES FARMACEUTICAS ASI PREPARADAS.FIG 5.
ES90101570T 1989-01-31 1990-01-26 Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co Expired - Lifetime ES2055175T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8919261A IT1229517B (it) 1989-01-31 1989-01-31 Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.

Publications (1)

Publication Number Publication Date
ES2055175T3 true ES2055175T3 (es) 1994-08-16

Family

ID=11156204

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90101570T Expired - Lifetime ES2055175T3 (es) 1989-01-31 1990-01-26 Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co

Country Status (9)

Country Link
US (1) US5538734A (es)
EP (1) EP0382019B1 (es)
JP (1) JPH0757727B2 (es)
AT (1) ATE88895T1 (es)
DE (1) DE69001493T2 (es)
DK (1) DK0382019T3 (es)
ES (1) ES2055175T3 (es)
GR (1) GR3007790T3 (es)
IT (1) IT1229517B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US5997915A (en) 1996-01-31 1999-12-07 South Alabama Medical Science Foundation Compositions for human and animal consumption containing reduced folates and methods for making and using same
DK1071425T3 (da) * 1998-04-24 2007-12-27 Scarista Ltd Behandling af depression og farmaceutiske præparater dertil
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
CN1311665A (zh) * 1998-08-03 2001-09-05 新生制药公司 一种新的止痛、抗炎和创伤治疗剂
JP2002527484A (ja) * 1998-10-19 2002-08-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング セントジョーンズワートならびにジヒドロおよびテトラヒドロ葉酸の誘導体を含有する、うつ病の治療および予防のための天然製剤
ATE235244T1 (de) * 1998-10-30 2003-04-15 Merck Patent Gmbh Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
JP2004538262A (ja) * 2000-12-14 2004-12-24 タフツ ユニバーシティー 関節炎状態を治療するための化合物および方法
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002303427A1 (en) * 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
AU2003269889B2 (en) * 2002-06-17 2007-04-19 Epigenesis Pharmaceuticals, Llc Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
EP2451299B1 (en) 2009-07-10 2016-04-06 Linzy O. Scott III Methods and compositions for treating thyroid-related medical conditions with reduced folates
EP2575825A4 (en) 2010-02-12 2014-01-01 Alexander Vuckovic M D Llc COMPOSITIONS AND METHODS FOR TREATING DEPRESSION
WO2018144088A1 (en) 2016-11-03 2018-08-09 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
AU2018246265B2 (en) 2017-03-31 2022-07-07 Merck Patent Gmbh Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572137A (en) * 1977-02-22 1980-07-23 Bioresearch Sas Del Dr Livio C Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts
GB2072504B (en) * 1980-03-27 1983-10-26 Coppen A J Pharmaceutical compositions
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8621268D0 (en) * 1986-09-03 1986-10-08 Univ Strathclyde Separation of substances
IT1204612B (it) * 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.

Also Published As

Publication number Publication date
DE69001493D1 (de) 1993-06-09
EP0382019A1 (en) 1990-08-16
IT1229517B (it) 1991-09-03
DE69001493T2 (de) 1993-08-26
US5538734A (en) 1996-07-23
EP0382019B1 (en) 1993-05-05
ATE88895T1 (de) 1993-05-15
JPH0757727B2 (ja) 1995-06-21
GR3007790T3 (es) 1993-08-31
JPH02240021A (ja) 1990-09-25
IT8919261A0 (it) 1989-01-31
DK0382019T3 (da) 1993-06-07

Similar Documents

Publication Publication Date Title
ES2055175T3 (es) Utilizacion del acido 5-metiltetrahidrofolico, del acido 5-formiltetrahidrofolico y de sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas de liberacion retardada adecuadas para la utilizacion en la terapia de trastornos depresivos, y las co
RU95109100A (ru) Производные ксантина, смесь их изомеров или отдельные изомеры и их фармакологически переносимые соли и фармацевтическая композиция с антагонистической в отношении аденозина активностью на их основе
DE69327432D1 (de) Heilmittel für wunden und hämorrhoiden
ES2062141T3 (es) Utilizacion de acido 5-metiltetrahidrofolico, acido 5-formiltetrahidrofolico, asi como sus sales farmaceuticamente aceptables, para la preparacion de composiciones farmaceuticas en forma de liberacion controlada y eficaces en la terapia de trastornos mentales organicos, y las cor
ES2193901T1 (es) Derivados de prostaglandina para el tratamiento de glaucoma o hipertension ocular.
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
ES2115725T3 (es) Hidrocloruro de triazoliltiometiltiocefalosporina, su hidrato cristalino y la preparacion de este.
ES2091766T3 (es) Uso de n-butil-desoxinojirimicina para el tratamiento de herpes.
MX9400037A (es) Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular.
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2020171T3 (es) Eteres de 1-bencil-3-hidroximetilindazol con 2-hidroxiacidos alifaticos.
MX9300399A (es) Derivados heterotriciclicos.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES2067864T3 (es) Tratamiento de la hipertension ocular con una combinacion sinergica para administracion ocular.
ES2093782T3 (es) Piridazindionas y su uso en el tratamiento de trastornos neurologicos.
ES8605532A1 (es) Un procedimiento para preparar derivados de aminoglicosido
DE69108408D1 (de) 4,5-dihydroxy und 4,5,8-trihydroxy-9,10-dioxo-2-anthracencarbonsäure-dikohlensäureester und urethane mit therapeutischer wirkung.
ES2037095T3 (es) Un procedimiento para preparar una composicion farmaceutica.
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ES534859A0 (es) Procedimiento para la obtencion de derivados de 1-(4'-alquilsulfonilfenil)-2-amino-1,3-propandiol n-substituidos
ES2059058T3 (es) Combinacion sinergica para uso oftalmico.
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 382019

Country of ref document: ES